Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005642 | 1.00 | KMT2A (0.34) | KMT2ASMN1; SMN2COMTMAPTCYP1A2 | |
| SCHEMBL14048787 | 0.77 | — | — | |
| SCHEMBL2998093 | 0.73 | POLB (0.44) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2998092 | 0.73 | POLB (0.44) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24792709 | 0.72 | KMT2A (0.34) | KMT2ASMN1; SMN2COMTMAPT | |
| SCHEMBL18949206 | 0.72 | KMT2A (0.34) | KMT2ASMN1; SMN2COMT | |
| SCHEMBL23457288 | 0.72 | — | — | |
| SCHEMBL16333669 | 0.71 | KMT2A (0.42) | KMT2ASMN1; SMN2COMT | |
| SCHEMBL16333670 | 0.71 | KMT2A (0.42) | KMT2ASMN1; SMN2COMT | |
| SCHEMBL332480 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| EP-1982987-A1 | Spiro-pyrano-pyrazole derivatives | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | SIGMAR1, TMEM97, OPRD1 | KMT2A 4514/4885SMN1; SMN2 4110/4885COMT 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.